[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-dysfunction":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100494256","phase-3-mechanisms-and-safety-of-sglt2-inhibition-in-peritoneal-dialysis-100494256",false,"NCT05715814","meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis","A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function","CANARY","Inclusion Criteria:\n\n* Signed and dated written informed consent.\n* Patients aged ≥18 years on PD with RKF defined as at least 250 cc of urine output per day (assessed via 24-hour urine collection) and a minimum measured GFR of 2 ml\u002Fmin\u002F1.73m2, as measured at least once in the last 3 months.\n* Stable PD prescription, as determined by investigators.\n* Stable dose of RAAS blockade if on a medication within this class for the last 30 days.\n\nExclusion Criteria:\n\n* Type 1 diabetes.\n* Recent (in the 30 days prior to screening) acute coronary syndrome or cerebrovascular event.\n* PD peritonitis within 30 days of screening.\n* History of organ transplant, including pancreas, pancreatic islet cells or kidney transplant.\n* Planned surgery\u002Fprocedures or radiologic investigations requiring contrast during the trial.\n* Pregnant, planning to become pregnant, or nursing an infant during the study period\n* History of any DKA event\n* Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, hemolytic anemia) at screening.\n* Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.\n* Alcohol or drug abuse within the 3 months prior to screening that would interfere with trial participation based on Investigator's judgement.\n* Use of SGLT2 inhibitor within 30 days prior to screening.\n* Intake of an investigational drug in another trial within 30 days prior to screening.\n* Patient not able to understand and comply with study requirements, based on Investigator's judgment.\n* Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome (e.g. immunocompromised patients, active malignancy, patients who might be at higher risk of developing genital or mycotic infections, patients with chronic viral infections, uncontrolled hypertension, cardiorenal and\u002For hepatorenal syndrome, severe hepatic impairments etc.).","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).",[27,28,29,30,31],"Peritoneal Dialysis Complication","End Stage Kidney Disease","Sodium-glucose Co-transporter-2 Inhibitors","Kidney Dysfunction","Residual Kidney Function","RECRUITING","2026-04-30",{"date":35,"type":36},"2026-05-01","ACTUAL",{"date":38,"type":36},"2024-09-01",{"date":40,"type":21},"2027-12-01",{"name":42,"class":43},"University Health Network, Toronto","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100591692","early-phase-1-the-kidneys-response-to-exercise-in-heat-and-the-impact-of-vitamin-b3-on-this-response-100591692","NCT06983730","The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response","Development of a Clinical Experimental Heat Stress Protocol and Exploration of the Effect of Niacinamide on Physiologic, Metabolic, and Biochemical Responses to Heat Stress","Inclusion Criteria:\n\n* Healthy volunteer\n* Any race\n* Estimated glomerular filtration rate greater than 90 ml\u002Fmin\u002F1.73m2\n* Urine albumin\u002Fcreatinine ratio less than 30mg\u002Fg\n* Nonsmoker\n* No regular dietary supplements, particularly vitamin B3\n* Physically fit, defined as having a VO2 max of between 35 and 60mL\u002Fkg\u002Fmin\n\nExclusion Criteria:\n\n* Medical condition preventing safe participation in exercise during heat\n* Allergy to Vitamin B3\n* Severe food allergies or dietary restrictions that would preclude eating the planned study diet without major modifications",true,"45 Years",{"count":55,"type":21},28,[57],"EARLY_PHASE1","The goal of this clinical trial is to learn about the processes occurring in the kidneys while under heat stress in healthy volunteers. The main questions it aims to answer are:\n\n* How do the chemicals produced by the body change under conditions of higher versus lower heat stress?\n* What role does a specific area of the body's metabolism, known as NAD+ metabolism, play in the body's response to heat stress, and can this response be modified by taking vitamin B3?",[60,61,30],"Heat Strain","Healthy Volunteer Study",[63,64,65,66],"NAD+","Niacinamide","Vitamin B3","Experimental heat strain","2026-02-03",{"date":69,"type":36},"2026-02-05",{"date":71,"type":36},"2026-01-26",{"date":73,"type":21},"2028-06",{"name":75,"class":43},"Beth Israel Deaconess Medical Center",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":52,"sex":17,"minAge":85,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":108,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":44},"100420250","pediatric-hypertension-and-the-renin-angiotensin-system-phrase-100420250","NCT04752293","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage","PHRASE","INCLUSION CRITERIA: HYPERTENSION COHORT\n\n* 7-18 years of age at time of enrollment\n* Confirmed new diagnosis of primary hypertension: no identifiable secondary cause, referred to hypertension or nephrology clinic\n\n  * Age \\\u003C13 years: BP ≥95th %ile or ≥130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥130\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: HYPERTENSION COHORT\n\n* \\\u003C7 years or \\>18 years of age at time of enrollment\n* BP confirmed as normal or in the elevated BP category based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C95th %ile or \\\u003C130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C130\u002F80 mmHg\n* A confirmed secondary cause of hypertension\n* Confounding medical condition (heart or kidney disease \\[except hypertension-associated heart changes on echocardiogram or albuminuria\\], vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State\n\nINCLUSION CRITERIA: CONTROL COHORT\n\n* 7-18 years of age at time of enrollment\n* Normal BP based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C90th %ile or \\\u003C120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C120\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: CONTROL COHORT\n\n* \\\u003C7 or \\>18 years of age at time of enrollment\n* Elevated BP or hypertension, based on ≥3 prior office BP measurements on separate days:\n\n  * Age \\\u003C13 years: BP ≥90th %ile or ≥120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥120\u002F80 mmHg\n* History of elevated BP or hypertension\n* Current use of BP-lowering medications\n* Confounding medical condition (heart or kidney disease, vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State","7 Years",{"count":87,"type":21},125,"OBSERVATIONAL","Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.",[91,92,93,94,95,96,97,30,98,99,100,101,102,103,104,105,106,107],"Hypertension","Left Ventricular Hypertrophy","Left Ventricular Dysfunction","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Diseases","Kidney Injury","Sodium Urine High","Blood Pressure Disorders","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Proteinuria","Albuminuria",[109,110,91,111,112,92,107,113,114,115,116,117,118,119,120,121,122,123,124,125,95,97,126,127,105,128,129,130,131],"High Blood Pressure","Elevated Blood Pressure","Pediatric Hypertension","Target Organ Damage","Uric Acid","Klotho","Fibroblast Growth Factor 23","Renin-Angiotensin-Aldosterone System","Renin-Angiotensin System","Angiotensin-(1-7)","Angiotensin II","Angiotensin-Converting Enzyme 2","Angiotensin-Converting Enzyme","Causal Inference","Causal Mediation Analysis","Sensitivity Analysis","Predictive Analysis","Heart Rate Variability","Sodium","Lifecourse","Kidney Function","Ambulatory Blood Pressure Monitoring","Echocardiogram","2025-12-04",{"date":134,"type":36},"2025-12-11",{"date":136,"type":36},"2021-05-19",{"date":138,"type":21},"2026-12",{"name":140,"class":43},"Wake Forest University Health Sciences"]